

## **LIFECARE ASA: UPDATED COMPANY PRESENTATION**

**Bergen, Norway, 23 April 2025 - Lifecare ASA (LIFE), a medtech company developing next generation continuous glucose monitoring (CGM) solutions for diabetes management, today publishes an updated company presentation articulating the company's long-term value creation opportunity.**

The presentation is attached and available at: <https://lifecare.no/investor/>

### **Key highlights from the presentation:**

#### *Diabetes is a trillion-dollar global healthcare challenge*

- CGMs the fastest growing diabetes tech segment, representing a USD 30 billion market opportunity
- Within CGMs, implantable solutions represent a USD 5 billion potential market

#### *Strong value drivers in place 2025-2028*

- Set to capitalize on "second mover" advantage, leveraging first mover regulatory approvals in the US
- Capital efficient path to commercialization with partner-led go-to-market strategy and minimal additional R&D
- Near-term value inflection points including veterinary market launch late 2025, CE mark in 2026, and European human market launch in 2027

#### *Significant value creation potential*

- Peak revenue potential of USD 1 billion + on realistic market assumptions
- Revenue sustainable at high levels long-term assuming conservative market share in a growing market
- EBITDA margin of 35%+

### **About us**

Lifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's main focus is to bring the next generation of Continuous Glucose Monitoring ("**CGM**") systems to market. Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor technology is referred to as "Sencell" and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.



**PRESS RELEASE**  
23 April 2025 07:00:00 CEST

### **Contacts**

For further information, please contact:

Joacim Holter, CEO, [joacim.holter@lifecare.no](mailto:joacim.holter@lifecare.no), +47 40 05 90 40

Renete Kaarvik, CFO, [renete.kaarvik@lifecare.no](mailto:renete.kaarvik@lifecare.no), +47 94 83 82 42

### **Attachments**

[Lifecare Company Presentation April 2025](#)